Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results

The latest announcement is out from Oric Pharmaceuticals ( (ORIC) ).

Oric Pharmaceuticals announced an update on their ORIC-944 clinical trials, highlighting the drug’s strong clinical activity when combined with apalutamide and darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with abiraterone. The Phase 1b trial, which involves 20 patients, showed promising PSA response rates, with ongoing dose optimization expected to provide further data in the first quarter of 2026. This development could enhance Oric’s position in the oncology market by potentially offering a new therapeutic option for mCRPC patients.

The most recent analyst rating on (ORIC) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Spark’s Take on ORIC Stock

According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.

Oric Pharmaceuticals’ overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company’s stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.

To see Spark’s full report on ORIC stock, click here.

More about Oric Pharmaceuticals

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for cancer. The company is engaged in the development of innovative drugs, with a particular emphasis on advancing treatments for prostate cancer.

Average Trading Volume: 1,250,751

Technical Sentiment Signal: Buy

Current Market Cap: $1.21B

Learn more about ORIC stock on TipRanks’ Stock Analysis page.